PTGX News and Press, Protagonist Therapeutics Inc. From 02/07/24

JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. NEWARK, CA / ACCESSWIRE / February 7, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or ...

2024-02-01 09:12:12 ET Protagonist Therapeutics ( NASDAQ: PTGX ) shares gained around 6% premarket on Thursday after the biopharma firm entered into a global license and collaboration deal with Takeda ( NYSE: TAK ) for the development and commercialization of its inv...

2024-01-31 17:03:58 ET Gainers: Nextracker  ( NXT ) +15% . Align Technology ( ALGN ) +11% . EZCORP ( EZPW ) +9% . Protagonist Therapeutics ( PTGX ) +8% . Cimpress ( CMPR ) +8% . Losers: MaxLinear ( MXL ) -8% ...

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Ve...

NEWARK, CA / ACCESSWIRE / January 29, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Guggenheim Healthcare Talks Annual Biotechnology ...

NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a presentation and host one-on-one meetings with investors at the 42nd Annual J.P. M...

2023-12-23 06:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-14 09:47:07 ET Energy Fuels Inc (UUUU) UUUU is trading DOWN for the last 4 days, and it at trading at $7.32 with volume of 731,818 and a one day change of $-0.07 (-0.88%). Energy Fuels Inc has a 52-week low of 5.01 and a 52-week high of $9.02. The business's 50-day moving av...

NEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to evaluate the safety and effectiveness of JNJ-211...

Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera Analysis of PACIFIC Phase 2 study shows that rusfertide improves markers of iron deficiency in patien...